FDA raises cardio concerns on Forest’s new COPD drug – FierceBiotech
FDA raises cardio concerns on Forest's new COPD drug FierceBiotech Forest Laboratories ($FRX) and Almirall got a thumbs up from the FDA for their efficacy data on a COPD drug candidate. But regulators want an upcoming panel review to closely explore cardio risks linked with the entire drug class it belongs to. |